Community curated by people like you

Pelacarsen stories

Sep 5, 2026

Novartis cholesterol drug pelacarsen fails in major clinical trial

Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.

Sep 5, 2026·2 sources

00

Top claims

▪Amgen's experimental lipoprotein(a)-lowering drug reduced lipoprotein(a) levels by more than 95% in mid-stage clinical testing
▪The Phase 3 clinical trial of pelacarsen included more than 8,000 participants who received either a combination of pelacarsen and standard medications or typical therapies and a placebo
▪In an earlier clinical trial, pelacarsen decreased lipoprotein(a) levels in study participants by as much as 80% after 24 weeks, according to William Blair analyst Myles Minter

Topics

Clinical trials Cardiovascular diseases